Skip to main content
. 2017 Jan;33(1):34–40. doi: 10.6515/ACS20160303A

Table 1. The distributions of the selected variables in the CAD cases and controls.

Variable CAD (n = 435) Controls (n = 480) p
Mean age, y 61.30 (±9.71) 60.79 (±7.54) 0.38
Woman, % 155 (35.6) 184 (38.3) 0.40
Mean BMI, kg/m2 25.99 (±3.28) 26.24 (±2.75) 0.22
Family history of CAD, % 98 (22.5) 63 (13.1) < 0.001
Previous smoker, % 247 (56.8) 211 (44.0) < 0.001
Previous drinker, % 82 (18.9) 81 (16.9) 0.44
Hypertension, % 305 (70.1) 297 (61.9) 0.009
Hyperlipidemia, % 274 (63.0) 286 (59.6) 0.29
Diabetes mellitus, % 113 (26.0) 90 (18.8) 0.009
Previous stroke, % 22 (5.1) 11 (2.3) 0.03
Previous myocardial infarction, % 100 (23.0)
Previous percutaneous coronary intervention, % 221 (50.8)
Previous coronary artery bypass grafting, % 41 (9.4)
Fasting blood glucose (mmol/l) 5.92 (±2.25) 5.41 (±1.07) < 0.001
Uric acid (μmol/l) 325.82 (±85.40) 312.60 (±79.60) 0.02
Creatinine (μmol/l) 68.69 (±18.02) 62.84 (±21.45) < 0.001
Total cholesterol (mmol/l) 4.70 (±1.07) 4.86 (±2.85) 0.28
Triglyceride (mmol/l) 1.89 (±1.67) 1.64 (±0.95) 0.006
High density lipoprotein (mmol/l) 1.03 (±0.24) 1.16 (±0.33) < 0.001
Low density lipoprotein (mmol/l) 3.02 (±0.93) 3.07 (±0.83) 0.40
Fibrinogen (g/l) 2.74 (±0.64) 2.61 (±0.62) 0.002
Aspirin, % 427 (98.2) 414 (88.5) < 0.001
Clopidogrel, % 312 (71.7) 15 (3.2) < 0.001
Nitroglycerin, % 350 (80.6) 61 (13.0) < 0.001
Angiotensin converting enzyme inhibitor, % 148 (34.1) 126 (27.0) 0.02
Angiotensin II receptor blockers, % 97 (22.4) 74 (15.8) 0.01
β-blocker, % 333 (76.6) 230 (49.1) < 0.001
Ca2+ antagonist, % 171 (39.4) 156 (33.3) 0.06
Statins, % 418 (96.1) 310 (66.2) < 0.001
Diuretics, % 41 (9.5) 21 (4.5) 0.003
Insulin, % 37 (8.5) 10 (2.1) < 0.001
Oral hypoglycemic drugs, % 102 (23.5) 55 (11.8) < 0.001

BMI, body mass index; CAD, coronary artery disease; Ca2+, calcium channels. Bold values are statistically significant (p < 0.05); The medical information was available in 433-435 CAD cases and 465-468 non-CAD controls.